Page last updated: 2024-10-25

deferoxamine and Leukemia, T-Cell

deferoxamine has been researched along with Leukemia, T-Cell in 1 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Leukemia, T-Cell: A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gharagozloo, M1
Khoshdel, Z1
Amirghofran, Z1

Other Studies

1 other study available for deferoxamine and Leukemia, T-Cell

ArticleYear
The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine.
    European journal of pharmacology, 2008, Jul-28, Volume: 589, Issue:1-3

    Topics: Antioxidants; Apoptosis; Cell Cycle; Cell Proliferation; Cell Survival; Deferoxamine; DNA Replicatio

2008